Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $38.9 million versus the consensus estimate of $34.25 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.